Dr. Feng-Ming Tien on immune landscapes and the future of AML risk stratification
In this video interview from SOHO Asia 2026, Dr. Feng-Ming Tien discusses the critical link between the immune microenvironment and therapeutic success in
SOHO Asia 2026
Leukemia
Acute Myeloid Leukemia
News
Video Interviews
Cellular Therapy
Multiple Myeloma
News
Japan’s PMDA clears phase 3 trial of eque-cel in relapsed or refractory MM
The clearance allows the expansion of an international, phase 3 trial (CT103AC004) into Japan. This multi-center study evaluates the efficacy and safety of
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
CAR-T improves survival, reduces hospital use in R/R LBCL
The retrospective, single-center cohort study used linked data from the Princess Margaret Cancer Centre lymphoma database.
SOHO 2026
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Aggressive B-Cell Lymphomas
Indolent B-Cell Lymphomas
Mantle Cell Lymphoma
T-Cell Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Society Updates
Registration now open for SOHO 2026, receive early bird rates until June 10
Registration is now officially open for the Fourteenth Annual Meeting of the Society of Hematologic Oncology. The event is scheduled for September 9
Community Oncology News
Trending now
Community Oncology
Cellular Therapy
Multiple Myeloma
Video Interviews
Dr. Jeffrey Matous on managing access to novel agents in the community setting
Live session held on March 18, 2026, from 2:30 – 3 pm CT with speaker Jeffrey Matous presenting on "Managing access to novel
Lymphoma
Aggressive B-Cell Lymphomas
News
EC approves nivolumab and BV for relapsed or refractory cHL
The European Commission (EC) has approved nivolumab (Opdivo®) in combination with brentuximab vedotin for the treatment of adult and pediatric patients with relapsed
Lymphoma
Aggressive B-Cell Lymphomas
Real-world analysis finds similar efficacy for 2nd-line axi-cel, liso-cel in R/R LBCL
The EBMT analysis was led by first author Anna Ossami Saidy of the Department of Hematology and Cell Therapy at Helios Klinikum Berlin-Buch
Lymphoma
Indolent B-Cell Lymphomas
News
Brazil regulatory agency approves tafasitamab combo in R/R follicular lymphoma
Beyond this new indication, the drug is already approved in Brazil and the European Union for relapsed or refractory diffuse large B-cell lymphoma,
2026 Tandem Meetings
Leukemia
Acute Myeloid Leukemia
Quizartinib similar to placebo in impact on AML patient-reported outcomes, QoL
Analysis of the QuANTUM-First phase 3 trial found that the impact of quizartinib on patient-reported outcomes and health-related quality of life (QoL) were
Cellular Therapy
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves subcutaneous mosunetuzumab in relapsed or refractory follicular lymphoma
The US Food and Drug Administration (FDA) approved mosunetuzumab (Lunsumio VELO), a CD20xCD3 bispecific antibody, as a subcutaneous formulation for adult patients with